Journal

Calcitonin gene-related peptide (CGRP): a new target for migraine.

Read time: 1 mins

Published:1st Jan 2019

Author: Russo AF.

Source: Annual Review of Pharmacology and Toxicology

Availability: Free full text

Ref.:Annu Rev Pharmacol Toxicol. 2015;55:533-52.

DOI:10.1146/annurev-pharmtox-010814-124701

Calcitonin gene-related peptide (CGRP): a new target for migraine

Migraine is a neurological disorder that manifests as a debilitating headache associated with altered sensory perception. The neuropeptide calcitonin gene-related peptide (CGRP) is now firmly established as a key player in migraine. Clinical trials carried out during the past decade have proved that CGRP receptor antagonists are effective for treating migraine, and antibodies to the receptor and CGRP are currently under investigation. Despite this progress in the clinical arena, the mechanisms by which CGRP triggers migraine remain uncertain. This review discusses mechanisms whereby CGRP enhances sensitivity to sensory input at multiple levels in both the periphery and central nervous system. Future studies on epistatic and epigenetic regulators of CGRP actions are expected to shed further light on CGRP actions in migraine. In conclusion, targeting CGRP represents an approachable therapeutic strategy for migraine.

Read abstract on library site Access full article